Proteomics

Dataset Information

0

Chronic lymphocytic leukaemia cells exhibit functional heterogeneity in the unfolded protein response: a proteomic study


ABSTRACT: Genomic, epigenomic, and transcriptomic studies have provided only a partial explanation of disease heterogeneity in chronic lymphocytic leukaemia (CLL). Since mRNA and protein expression do not always correlate, CLL heterogeneity was investigated using global cellular proteomics. Sequential Windowed Acquisition of All THeoretical fragments Mass Spectrometry (SWATH-MS) was applied to CLL samples obtained from patients undergoing initial treatment with fludarabine-containing chemoimmunotherapy. Two independent proteomic datasets were generated: one compared pre-treatment samples from 32 patients who achieved an optimal versus suboptimal therapy response; the other compared paired samples from 16 patients collected before treatment and at disease progression. eIF2 signalling, which is pivotal to the unfolded protein response (UPR), was identified by Ingenuity Pathway Analysis as the most enriched pathway in both datasets. eIF2 signalling was also identified as the top pathway in a fludarabine-resistant CLL cell line established from HG3 cells. Measurement of key components of the eIF2 signalling pathway by Western blotting showed that fludarabine-resistant HG3 cells expressed higher levels of PERK, which phosphorylates the regulatory eIF2α subunit, and lower levels of BiP, an HSP70 molecular chaperone that inactivates PERK but preferentially binds to misfolded proteins during ER stress. The PERK inhibitor, GSK2606414, sensitised resistant, but not sensitive, HG-3 cells to fludarabine without affecting background cell viability or cytotoxicity induced by venetoclax. These findings provide the first evidence of functionally important heterogeneity in the UPR of CLL cells and, in doing so, illustrate the value of global cellular proteomics as an investigative tool in assessing differential patient response to therapy.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): B Cell

DISEASE(S): Chronic Lymphocytic Leukemia

SUBMITTER: Rosalind Jenkins  

LAB HEAD: Rosalind Jenkins

PROVIDER: PXD058183 | Pride | 2025-08-04

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
Baseline_progression_study_DIANN_matrix.xlsx Xlsx
MRD_study_DIANN_matrix.xlsx Xlsx
Resistance_model_DIANN_matrix.xlsx Xlsx
UK_CLL_10_2_7_SWATH_050819.wiff Wiff
UK_CLL_10_2_7_SWATH_050819.wiff.scan Wiff
Items per page:
1 - 5 of 251
altmetric image

Publications

The unfolded protein response influences therapy outcome and disease progression in chronic lymphocytic leukaemia.

Khan Umair Tahir UT   Clarke Kim K   Eagle Gina G   Oates Melanie M   Hillmen Peter P   Jayne Sandrine S   Dyer Martin J S MJS   Phipps Alex A   Falciani Francesco F   Jenkins Rosalind E RE   Pettitt Andrew R AR  

Scientific reports 20250728 1


Since genomics, epigenomics and transcriptomics have provided only a partial explanation of chronic lymphocytic leukaemia (CLL) heterogeneity, and since concordance between mRNA and protein expression is incomplete, we related the CLL proteome to clinical outcome. CLL samples from patients who received fludarabine-containing chemoimmunotherapy were analysed by mass spectrometry (SWATH-MS). One dataset compared pre-treatment samples associated with an optimal versus suboptimal response, while ano  ...[more]

Similar Datasets

2012-01-20 | E-GEOD-29929 | biostudies-arrayexpress
2014-06-02 | GSE54581 | GEO
2012-01-20 | GSE29929 | GEO
2014-06-02 | E-GEOD-54581 | biostudies-arrayexpress
2017-12-18 | GSE98023 | GEO
2024-08-30 | GSE267095 | GEO
2024-09-02 | BIOMD0000000703 | BioModels
2024-05-22 | PXD052453 |
2024-08-10 | PXD043703 | Pride
2014-07-18 | E-GEOD-59535 | biostudies-arrayexpress